NFlection Therapeutics

NFlection Therapeutics is a company headquartered in the United States. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.

NFlection Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for rare dermatological disorders driven by aberrant activation of the RAS pathway. The company is developing first-in-class MEK inhibitors for topical treatment of conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.